BENEFIT OF CONTINUOUS GLUCOSE MONITORING (CGM) IN REDUCING HYPOGLYCEMIA IS SUSTAINED THROUGH 12 MONTHS OF USE AMONG OLDER ADULTS WITH TYPE 1 DIABETES (T1D)
- Kellee Miller, United States of America
- Kellee Miller, United States of America
- Lauren G. Kanapka, United States of America
- Michael R. Rickels, United States of America
- Richard Pratley, United States of America
Abstract
Background and Aims
The Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) randomized clinical trial demonstrated reductions in hypoglycemia with CGM compared with blood glucose monitoring over 6 months among older adults with T1D. To determine if this improvement could be sustained over a longer period with less intensive follow-up, participants in the CGM group continued CGM through 12 months.
Methods
Of the adults ≥60 years with T1D (in the RCT CGM group, 100 of 103 (97%) continued on CGM and completed 12 months of follow-up (58% female, median age 68 years, 92% non-Hispanic white, and 58% used insulin pumps). CGM-measured outcomes were calculated at baseline (masked CGM) and 4 weeks prior to each visit over 12 months.
Results
Median percent time <70 mg/dL was reduced from 5.0% at baseline to 2.8% at 12 months (p<0.001). This improvement was evident in the first month and sustained through 12 months (Figure). Similar improvements were observed for time <54 mg/dL (median 1.9% versus 0.4%; p<0.001). In addition, participants spent more time in range 70-180 mg/dL (mean 56% versus. 64%; p<0.001), spent less time in hyperglycemia >180 mg/dL (mean 37% vs. 33%; p<0.001), and had better HbA1c (mean 7.6% versus 7.4%; p=0.01) at 12 months compared with baseline. CGM use remained high with 85% using the sensor ≥6 days per week at both 6 and 12 months.
Conclusions
These results demonstrate CGM may be used effectively in older adults with T1D and provide evidence for further integrating this technology into clinical practice.